At different stages of lung cancer, IL-6's mechanisms upregulated CCL-2/5 and played a part in the EMT and therapy resistance, a recent study in in vivo mouse and in vitro human lung tumour representations indicated [5]. Here, CCL2 is linked to lung carcinoma.